New Indication: Neoadjuvant Cemiplimab for Cutaneous Squamous Cell Cancer

Phase 2, confirmatory, multicenter, nonrandomized study

Resectable stage II, III, or IV (M0) cutaneous squamous-cell carcinoma

Cemiplimab 350 mg/21 day (four doses) before surgery (N:79)

pCR: 40 (51%)

Pathological major response: 10 (13%)

ORR (imaging): 68%

Any grade AEs: 87%, serious event: 16%, fatigue:30%, diarrhea:14%, nausea:14%

Any grade ≥3 AEs: 18%, serious event: 13%, hyponatremia:3%

Reviewed by Hasan Cagri Yildirim, MD on Nov 26, 2022

cemiplimab